Clinical trials: Multiple Sclerosis, Secondary Progressive
Secondary Progressive Multiple Sclerosis
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.
- Trial name
- NCT01228396
- Testing
- Hyperimmune caprine serum against HIV lysate
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Daval International Limited
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Functional Outcomes From Diets in Multiple Sclerosis
The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS).
- Trial name
- FOOD_for_MS (NCT05327322)
- Testing
- Glycemic load, Calorie restriction, Behavioral support
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
This prospective cohort study is part of the Clinnova programme and aims to (i) identify clinical imaging and omics characteristics associated with early Multiple Sclerosis (MS) and with transitioning phases to progressive MS, as…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06526364
- Testing
- All participants will be asked to provide data and samples for collection and analysis.
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- University Hospital, Basel, Switzerland
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Metformin Treatment in Progressive Multiple Sclerosis
The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis
- Trial name
- NCT05349474
- Testing
- Metformin 500 Mg Oral Tablet, up to 4 tablets a day
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, Los Angeles
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting
Intermittent Hypoxia in Persons With Multiple Sclerosis
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06276634
- Testing
- Acute Intermittent Hypoxia
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Shirley Ryan AbilityLab
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
This was a multicenter, non-interventional, retrospective study aiming to evaluate the real-world effectiveness and safety of siponimod treatment in Chinese patients with relapsing forms of multiple sclerosis (RMS).
- Conditions
- Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- NCT06395909
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Novartis
Multiple Sclerosis
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
Phase IV open label, single-blind study, post-marketing, 1-year MRI observational study evaluating effect of Avonex® monotherapy (6.0 MIU administered i.m.
- Trial name
- NCT00463710
- Testing
- Avonex® monotherapy (6.0 MIU administered i.m. each week)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- State University of New York at Buffalo
Secondary Progressive Multiple Sclerosis
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
A present there is no safe treatment for reducing rate at which disability worsens in people with secondary progressive multiple sclerosis.
- Trial name
- NCT00257855
- Testing
- Lamotrigine
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- University College London Hospitals
Secondary Progressive Multiple Sclerosis
Acceptance Based Telephone Support When Transitioning to SPMS
What is the purpose of the study? People with Multiple Sclerosis often say that they feel less support is available after they are diagnosed with Secondary Progressive Multiple Sclerosis, compared to before they received this…
- Trial name
- AT-SPMS (NCT04239664)
- Testing
- Acceptance Based Telephone Support (ABS+UC)
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- University of Nottingham
Multiple Sclerosis
A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.
- Trial name
- NCT01318421
- Testing
- ELND002
- Volunteers
- 12 people
- Sponsor
- Elan Pharmaceuticals
Multiple Sclerosis
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better.
- Trial name
- NCT06220669
- Testing
- LY3541860
- Where
- 20 sites in United States, France and 5 more
- Volunteers
- 63 people
- Sponsor
- Eli Lilly and Company
Secondary Progressive Multiple Sclerosis
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in…
- Trial name
- NCT05826028
- Where
- 2 sites in Australia
- Volunteers
- 368 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS
The purpose of this research study is to investigate the effectiveness of a memory enhancement technique in persons with Multiple Sclerosis.
- Trial name
- STEM (NCT03983681)
- Testing
- Strategy-Based Training to Enhance Memory (STEM)
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Kessler Foundation
Multiple Sclerosis
Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)
The goal of this clinical trial is to determine whether treatment with indapamide can slow the rate of progression in patients with progressive forms of multiple sclerosis (MS).
- Trial name
- INDAMS (NCT07765212)
- Testing
- Indapamide
- Volunteers
- 75 people
- Sponsor
- Eva M.M. Strijbis
Relapsing-Remitting Multiple Sclerosis
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy.
- Trial name
- SOSTOS (NCT05090371)
- Testing
- Ofatumumab, Disease modifying treatment (DMT)
- Where
- 43 sites in United States, Canada
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients
Multiple sclerosis (MS) is a chronic inflammatory disorder affecting the central nervous system that is characterized pathologically by focal demyelinating lesions in the brain parenchyma.
- Trial name
- NCT02253264
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. MS, typical presents with progression of clinical symptoms which mainly include motor and cognitive impairment, as well as…
- Trial name
- NCT06436131
- Testing
- In-phase Bilateral Exercise, Conservative exercises
- Where
- Cyprus
- Volunteers
- 20 people
- Sponsor
- Cyprus University of Technology
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Sensitivity of Motor Assessment in MS - a Prospective Cohort Study
The study explores the application of marker-less motion analysis (visual-perceptive computing, VPC) using a consumer grade infrared and video camera (Microsoft Kinect) for clinical assessment in MS.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- MOTOSENS (NCT04993274)
- Testing
- PASS-MS
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Friedemann Paul
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
The purpose of the study is 1) to study the safety and tolerability of escalating doses of myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of T Cell Vaccine ion the clinical course of MS.
- Trial name
- DES (NCT00587691)
- Testing
- Tovaxin Autologous T Cell Vaccine
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Opexa Therapeutics, Inc.
Multiple Sclerosis
Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis
This trial is an investigator-initiated, single-arm, open-label Phase Ib/II study to observe the safety, tolerability, PK/PD characteristics, immunogenicity, and the efficacy of SYS6020 injection in participants with…
- Trial name
- NCT07756268
- Testing
- SYS6020 injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tongji Hospital